Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orforglipron (Primary) ; Atorvastatin; Midazolam; Simvastatin
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Adverse reactions; First in man
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 07 Jun 2022 Results assessing evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of LY in healthy subjects presented at the 82nd Annual Scientific Sessions of the American Diabetes Association
    • 17 Nov 2020 Status changed from recruiting to completed.
    • 04 Sep 2020 Planned End Date changed from 7 Dec 2020 to 4 Nov 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top